Next Article in Journal
The Role of Notch Signaling and Leptin-Notch Crosstalk in Pancreatic Cancer
Next Article in Special Issue
Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions
Previous Article in Journal
Use of References in Responses from Scandinavian Drug Information Centres
Previous Article in Special Issue
Pain Modulation after Oromucosal Cannabinoid Spray (SATIVEX®) in Patients with Multiple Sclerosis: A Study with Quantitative Sensory Testing and Laser-Evoked Potentials
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Medicines 2018, 5(3), 67;

Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain

Pain Management Research Institute, Kolling Institute of Medical Research, Northern Clinical School, Royal North Shore Hospital, University of Sydney, Sydney, New South Wales 2065, Australia
Author to whom correspondence should be addressed.
Received: 6 June 2018 / Revised: 27 June 2018 / Accepted: 27 June 2018 / Published: 1 July 2018
(This article belongs to the Special Issue Cannabinoids for Medical Use)
Full-Text   |   PDF [270 KB, uploaded 2 July 2018]


Chronic neuropathic pain is a prevalent condition that places a heavy burden on individuals and the healthcare system. Current medications have limitations and new approaches are needed, particularly given the current opioid crisis. There is some clinical evidence that the plant Cannabis sativa produces relief from neuropathic pain. However, current meta-analyses suggest that this efficacy is limited and there are problems with side effects. Most of this clinical research has examined whole cannabis, the psychoactive phytocannabinoid 9-tetrahydrocannabinol (THC), and nabiximols, which are a mixture of THC and the non-psychoactive phytocannabinoid cannabidiol. In the past, there has been little evidence based, preclinical animal research to guide clinical studies on phytocannabinoids. Recent animal studies indicate that while THC and high dose nabiximols are effective in animal neuropathic pain models, significant pain relief is only achieved at doses that produce substantial side effects. By contrast, cannabidiol and low dose nabiximols have moderate pain relieving efficacy, but are devoid of cannabinoid-like side effects. This animal data suggests that cannabidiol and low dose nabiximols warrant consideration for clinical studies, at least as adjuvants to current drugs. Preclinical research is also required to identify other phytocannabinoids that have therapeutic potential. View Full-Text
Keywords: cannabinoids; Cannabis sativa; phytocannabinoids; neuropathic pain; delta-9-tetrahydrocannabinol (THC); cannabidiol cannabinoids; Cannabis sativa; phytocannabinoids; neuropathic pain; delta-9-tetrahydrocannabinol (THC); cannabidiol
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Casey, S.L.; Vaughan, C.W. Plant-Based Cannabinoids for the Treatment of Chronic Neuropathic Pain. Medicines 2018, 5, 67.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Medicines EISSN 2305-6320 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top